Last reviewed · How we verify
CORT108297
At a glance
| Generic name | CORT108297 |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study) (PHASE2)
- Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CORT108297 CI brief — competitive landscape report
- CORT108297 updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI